Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation
- PMID: 31335448
- DOI: 10.1097/PGP.0000000000000627
Cervical Mesonephric Adenocarcinoma With Novel FGFR2 Mutation
Abstract
Mesonephric adenocarcinoma is a rare tumor, accounting for <1% of cervical cancers. Well-differentiated mesonephric adenocarcinoma can be difficult to distinguish from diffuse mesonephric hyperplasia. Herein, we report a case of well-differentiated mesonephric adenocarcinoma with an FGFR2 mutation not previously reported in the literature. Nonselective tyrosine kinase inhibitors or FGFR2 inhibitors may represent options for targeted therapy.
References
-
- Takenaka M, Saito M, Iwakawa R, et al. Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing. Int J Oncol 2015;46:2389–98.
-
- Sneeden VD. Mesonephric lesions of the cervix; a practical means of demonstration and a suggestion of incidence. Cancer 1958;11:334–6.
-
- Moritani S, Ioffe OB, Sagae S, et al. Mitotic activity and apoptosis in endocervical glandular lesions. Int J Gynecol Pathol 2002;21:125–33.
-
- McCluggage WG, Oliva E, Herrington CS, et al. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma. Histopathol 2003;43:144–50.
-
- Ordi J, Romagosa C, Tavassoli FA, et al. CD10 expression in epithelial tissues and tumors of the gynecologic tract: a useful marker in the diagnosis of mesonephric, trophoblastic, and clear cell tumors. Am J Surg Pathol 2003;27:178–86.
